FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053320975> ?p ?o ?g. }

• W2053320975 endingPage "862" @default.
• W2053320975 startingPage "855" @default.
• W2053320975 abstract "Objective Apathy occurs frequently following stroke and prior studies have demonstrated the negative effect of apathy on recovery from stroke. This study was a secondary analysis examining the efficacy of escitalopram, problem-solving therapy (PST), or placebo administered for 1 year to prevent the onset of apathy among patients with recent stroke. Methods Patients within 3 months of an index stroke who did not meet DSM-IV diagnostic criteria for major or minor depression and who did not have a serious comorbid physical illness were enrolled. Patients were recruited from three sites: University of Iowa, University of Chicago, and Burke Rehabilitation Hospital. One hundred fifty-four patients without evidence of apathy at initial evaluation were included in the randomized controlled trial using escitalopram (10 mg patients ≤65 years; 5 mg patients >65 years) (N = 51) or placebo (N = 47) or non-blinded PST (12 total sessions) (N = 56) over 1 year. At 3, 6, 9, and 12 months, patients were assessed for diagnosis and severity of apathy using the Apathy Scale. Results Using a Cox proportional hazards model of time to onset of apathy, participants given placebo were 3.47 times more likely to develop apathy than patients given escitalopram and 1.84 times more likely to develop apathy than patients given PST after controlling for age, sex, cognitive impairment, and diabetes mellitus status (adjusted hazard ratio: 3.47, 95% CI: 1.79–6.73 [escitalopram group]; adjusted hazard ratio: 1.84, 95% CI: 1.21–2.80 [PST group]). Conclusion Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo. Apathy occurs frequently following stroke and prior studies have demonstrated the negative effect of apathy on recovery from stroke. This study was a secondary analysis examining the efficacy of escitalopram, problem-solving therapy (PST), or placebo administered for 1 year to prevent the onset of apathy among patients with recent stroke. Patients within 3 months of an index stroke who did not meet DSM-IV diagnostic criteria for major or minor depression and who did not have a serious comorbid physical illness were enrolled. Patients were recruited from three sites: University of Iowa, University of Chicago, and Burke Rehabilitation Hospital. One hundred fifty-four patients without evidence of apathy at initial evaluation were included in the randomized controlled trial using escitalopram (10 mg patients ≤65 years; 5 mg patients >65 years) (N = 51) or placebo (N = 47) or non-blinded PST (12 total sessions) (N = 56) over 1 year. At 3, 6, 9, and 12 months, patients were assessed for diagnosis and severity of apathy using the Apathy Scale. Using a Cox proportional hazards model of time to onset of apathy, participants given placebo were 3.47 times more likely to develop apathy than patients given escitalopram and 1.84 times more likely to develop apathy than patients given PST after controlling for age, sex, cognitive impairment, and diabetes mellitus status (adjusted hazard ratio: 3.47, 95% CI: 1.79–6.73 [escitalopram group]; adjusted hazard ratio: 1.84, 95% CI: 1.21–2.80 [PST group]). Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo." @default.
• W2053320975 created "2016-06-24" @default.
• W2053320975 creator A5006975061 @default.
• W2053320975 creator A5013351783 @default.
• W2053320975 creator A5017286628 @default.
• W2053320975 creator A5019644135 @default.
• W2053320975 creator A5027585283 @default.
• W2053320975 creator A5034739870 @default.
• W2053320975 creator A5063173029 @default.
• W2053320975 creator A5066461508 @default.
• W2053320975 creator A5075206993 @default.
• W2053320975 creator A5079077303 @default.
• W2053320975 date "2013-09-01" @default.
• W2053320975 modified "2023-09-26" @default.
• W2053320975 title "Prevention of Poststroke Apathy Using Escitalopram or Problem-Solving Therapy" @default.
• W2053320975 cites W1575101351 @default.
• W2053320975 cites W192124739 @default.
• W2053320975 cites W1967292256 @default.
• W2053320975 cites W1973798645 @default.
• W2053320975 cites W1989844512 @default.
• W2053320975 cites W1997659839 @default.
• W2053320975 cites W2012658469 @default.
• W2053320975 cites W2015006744 @default.
• W2053320975 cites W2029111311 @default.
• W2053320975 cites W2030120831 @default.
• W2053320975 cites W2032217300 @default.
• W2053320975 cites W2044499887 @default.
• W2053320975 cites W2044815056 @default.
• W2053320975 cites W2049338685 @default.
• W2053320975 cites W2067131879 @default.
• W2053320975 cites W2077699169 @default.
• W2053320975 cites W2126507967 @default.
• W2053320975 cites W2128711456 @default.
• W2053320975 cites W2140658948 @default.
• W2053320975 cites W2141644074 @default.
• W2053320975 cites W2148239264 @default.
• W2053320975 cites W2149105567 @default.
• W2053320975 cites W2149950769 @default.
• W2053320975 cites W74099017 @default.
• W2053320975 doi "https://doi.org/10.1016/j.jagp.2012.07.003" @default.
• W2053320975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23930743" @default.
• W2053320975 hasPublicationYear "2013" @default.
• W2053320975 type Work @default.
• W2053320975 sameAs 2053320975 @default.
• W2053320975 citedByCount "33" @default.
• W2053320975 countsByYear W20533209752013 @default.
• W2053320975 countsByYear W20533209752014 @default.
• W2053320975 countsByYear W20533209752015 @default.
• W2053320975 countsByYear W20533209752016 @default.
• W2053320975 countsByYear W20533209752017 @default.
• W2053320975 countsByYear W20533209752018 @default.
• W2053320975 countsByYear W20533209752019 @default.
• W2053320975 countsByYear W20533209752020 @default.
• W2053320975 countsByYear W20533209752021 @default.
• W2053320975 countsByYear W20533209752022 @default.
• W2053320975 countsByYear W20533209752023 @default.
• W2053320975 crossrefType "journal-article" @default.
• W2053320975 hasAuthorship W2053320975A5006975061 @default.
• W2053320975 hasAuthorship W2053320975A5013351783 @default.
• W2053320975 hasAuthorship W2053320975A5017286628 @default.
• W2053320975 hasAuthorship W2053320975A5019644135 @default.
• W2053320975 hasAuthorship W2053320975A5027585283 @default.
• W2053320975 hasAuthorship W2053320975A5034739870 @default.
• W2053320975 hasAuthorship W2053320975A5063173029 @default.
• W2053320975 hasAuthorship W2053320975A5066461508 @default.
• W2053320975 hasAuthorship W2053320975A5075206993 @default.
• W2053320975 hasAuthorship W2053320975A5079077303 @default.
• W2053320975 hasConcept C118552586 @default.
• W2053320975 hasConcept C126322002 @default.
• W2053320975 hasConcept C127413603 @default.
• W2053320975 hasConcept C139719470 @default.
• W2053320975 hasConcept C142724271 @default.
• W2053320975 hasConcept C15744967 @default.
• W2053320975 hasConcept C162324750 @default.
• W2053320975 hasConcept C168563851 @default.
• W2053320975 hasConcept C169900460 @default.
• W2053320975 hasConcept C1862650 @default.
• W2053320975 hasConcept C204787440 @default.
• W2053320975 hasConcept C207103383 @default.
• W2053320975 hasConcept C27081682 @default.
• W2053320975 hasConcept C2776509080 @default.
• W2053320975 hasConcept C2776867660 @default.
• W2053320975 hasConcept C2779177272 @default.
• W2053320975 hasConcept C2779583969 @default.
• W2053320975 hasConcept C2780645631 @default.
• W2053320975 hasConcept C44249647 @default.
• W2053320975 hasConcept C558461103 @default.
• W2053320975 hasConcept C71924100 @default.
• W2053320975 hasConcept C78519656 @default.
• W2053320975 hasConceptScore W2053320975C118552586 @default.
• W2053320975 hasConceptScore W2053320975C126322002 @default.
• W2053320975 hasConceptScore W2053320975C127413603 @default.
• W2053320975 hasConceptScore W2053320975C139719470 @default.
• W2053320975 hasConceptScore W2053320975C142724271 @default.
• W2053320975 hasConceptScore W2053320975C15744967 @default.
• W2053320975 hasConceptScore W2053320975C162324750 @default.
• W2053320975 hasConceptScore W2053320975C168563851 @default.
• W2053320975 hasConceptScore W2053320975C169900460 @default.

• next